Observational studyJournal of the American Heart Association2026
Tirofiban Versus Alteplase for Patients With Minor Acute Ischemic Stroke: A Target Trial Emulation Study.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTirofiban has emerged as a potential treatment for acute ischemic stroke. We aimed to evaluate the efficacy and safety of tirofiban in patients with minor stroke within 4.5 hours of symptom onset.
methodsWe emulated a target trial using observational data. Patients with minor stroke (National Institutes of Health Stroke Scale score ≤5) who received tirofiban or alteplase within 4.5 hours were included. The primary outcome was excellent functional outcome (modified Rankin Scale score 0-1) at 90 days. Secondary outcomes included modified Rankin Scale score of 0 to 2 at 90 days, 24-hour National Institutes of Health Stroke Scale changes, ordinal shift in modified Rankin Scale, and early neurological deterioration or improvement. Safety outcomes included symptomatic intracranial hemorrhage, intracranial hemorrhage, any bleeding, and 90-day all-cause death.
resultsOf 677 eligible patients, 369 received tirofiban and 308 received alteplase. There was no significant difference in 90-day modified Rankin Scale score of 0 to 1 between groups (risk ratio, 1.06 [95% CI, 0.97-1.16];
conclusionsIn minor acute ischemic stroke treated within 4.5 hours, intravenous tirofiban showed no significant difference in 90-day functional outcomes relative to alteplase and was associated with lower risks of early neurological deterioration and bleeding, suggesting it could be considered a potential treatment option pending further randomized trials. REGISTRATION: URL: https://www.chictr.org.cn; Unique Identifier: ChiCTR2500106107.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.